Please assess the completion status of the following clinical trial:

Trial Title: Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient age ≥ 5 years~2. Presence of P. knowlesi malaria, confirmed by positive blood smear with asexual forms of P. knowlesi.~3. Temperature \>38C on admission or fever during the preceding 48 hours~4. Enrolled within 18 hours of commencing antimalarial treatment~5. Written informed consent from patient or attending relative able to and willing to give informed consent. Consent form and information sheets will be translated into Malay and copies provided to the patient.~Exclusion Criteria:~1. Patient or relatives unable or unwilling to give informed consent~2. Contraindication or allergy to paracetamol or artesunate therapy~3. Known cirrhosis, or \>6 standard alcoholic drinks/day~4. Pregnancy

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paracetamol (Type: EXPERIMENTAL): \>50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.~\<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine.
- No Paracetamol (Type: NO_INTERVENTION): No Paracetamol plus IV artesunate or oral artemether/lumefantrine.~If temperature \>39.5°C, tepid sponging and mechanical antipyresis will be performed by research staff and/or relatives.

Based on this trial design, predict the completion outcome and termination type (if applicable).